BR112016014236A2 - Agente profilático e terapêutico para o distúrbio do déficit de atenção/hiperatividade - Google Patents

Agente profilático e terapêutico para o distúrbio do déficit de atenção/hiperatividade

Info

Publication number
BR112016014236A2
BR112016014236A2 BR112016014236A BR112016014236A BR112016014236A2 BR 112016014236 A2 BR112016014236 A2 BR 112016014236A2 BR 112016014236 A BR112016014236 A BR 112016014236A BR 112016014236 A BR112016014236 A BR 112016014236A BR 112016014236 A2 BR112016014236 A2 BR 112016014236A2
Authority
BR
Brazil
Prior art keywords
hyperactivity disorder
prophylactic
drug
therapeutic agent
attention deficit
Prior art date
Application number
BR112016014236A
Other languages
English (en)
Inventor
Togashi Hiroko
Hiraide Sachiko
Yoneda Fumio
Takahata Kazue
Original Assignee
Fujimoto Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujimoto Co Ltd filed Critical Fujimoto Co Ltd
Publication of BR112016014236A2 publication Critical patent/BR112016014236A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

AGENTE PROFILÁTICO E TERAPÊUTICO PARA O DISTÚRBIO DO DÉFICIT DE ATENÇÃO/HIPERATIVIDADE. O 1-(benzofuran-2-il)-2-propilaminopentano ou um sal de adição de ácido farmacologicamente aceitável deste já é conhecido por apresentar uma excelente atividade/efeito como um medicamento an-tidepressivo, um medicamento psicotrópico, um medicamento para a doença anti-Parkinson e um medicamento para a doença anti-Alzheimer. No entanto, é verdadeiramente desconhecido que o composto é eficaz para a prevenção ou o tratamento do distúrbio de déficit de atenção/hiperatividade (ADHD). A presente invenção recentemente descobriu que o 1-(benzofuran-2-il)-2-propilaminopentano ou um sal de adição de ácido farmacologicamente aceitável deste é eficaz para a prevenção ou o tratamento do ADHD. Como um resultado, a presente invenção foi executada.
BR112016014236A 2013-12-25 2014-12-15 Agente profilático e terapêutico para o distúrbio do déficit de atenção/hiperatividade BR112016014236A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013266498 2013-12-25
PCT/JP2014/083100 WO2015098591A1 (ja) 2013-12-25 2014-12-15 注意欠如・多動性障害の予防および治療剤

Publications (1)

Publication Number Publication Date
BR112016014236A2 true BR112016014236A2 (pt) 2017-08-08

Family

ID=53478455

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016014236A BR112016014236A2 (pt) 2013-12-25 2014-12-15 Agente profilático e terapêutico para o distúrbio do déficit de atenção/hiperatividade

Country Status (14)

Country Link
US (1) US9782383B2 (pt)
EP (1) EP3087984B1 (pt)
JP (1) JP6518397B2 (pt)
KR (1) KR102280552B1 (pt)
CN (1) CN106163514B (pt)
AU (1) AU2014371437B2 (pt)
BR (1) BR112016014236A2 (pt)
CA (1) CA2932301A1 (pt)
DK (1) DK3087984T3 (pt)
ES (1) ES2864669T3 (pt)
IL (1) IL246872B (pt)
RU (1) RU2708694C2 (pt)
SI (1) SI3087984T1 (pt)
WO (1) WO2015098591A1 (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100572900B1 (ko) 1997-08-07 2006-04-24 후지모토 쿄다이 가부시키가이샤 에틸아민 유도체
US6210705B1 (en) 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
JP4499208B2 (ja) * 1998-10-29 2010-07-07 株式会社フジモト・コーポレーション 新規な光学活性アミノペンタン誘導体
DE19934592C2 (de) 1999-07-23 2003-10-23 Benckiser Nv Vorrichtung zur Aufnahme und dosierten Abgabe einer aktiven Zusammensetzung in eine Waschmaschine, einen Wäschetrockner oder eine Geschirrspülmaschine
JP4953040B2 (ja) 2001-09-19 2012-06-13 株式会社フジモト・コーポレーション アポトーシス抑制剤
JP5030194B2 (ja) 2004-11-25 2012-09-19 国立大学法人九州大学 薬物依存症治療剤
CA2612290C (en) 2005-06-28 2014-10-07 Fujimoto Co., Ltd. Process for preparing optically active aminopentane derivative, intermediate and process for preparing intermediate
WO2008095221A1 (en) * 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
JP2011529923A (ja) * 2008-08-06 2011-12-15 ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法
SG175420A1 (en) * 2009-05-12 2011-12-29 Albany Molecular Res Inc 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof

Also Published As

Publication number Publication date
IL246872B (en) 2021-03-25
JPWO2015098591A1 (ja) 2017-03-23
JP6518397B2 (ja) 2019-05-22
SI3087984T1 (sl) 2021-08-31
RU2708694C2 (ru) 2019-12-11
WO2015098591A1 (ja) 2015-07-02
EP3087984A1 (en) 2016-11-02
EP3087984A4 (en) 2017-08-23
KR20160096184A (ko) 2016-08-12
CN106163514B (zh) 2019-07-19
RU2016129912A (ru) 2018-01-30
DK3087984T3 (da) 2021-06-14
EP3087984B1 (en) 2021-04-07
US9782383B2 (en) 2017-10-10
AU2014371437B2 (en) 2020-01-30
US20160296495A1 (en) 2016-10-13
ES2864669T3 (es) 2021-10-14
RU2016129912A3 (pt) 2018-07-06
CA2932301A1 (en) 2015-07-02
AU2014371437A1 (en) 2016-06-16
CN106163514A (zh) 2016-11-23
IL246872A0 (en) 2016-09-29
KR102280552B1 (ko) 2021-07-26

Similar Documents

Publication Publication Date Title
EA201690372A1 (ru) Азапиридоновые соединения и их применение
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
UY36071A (es) Compuesto de ciclopropanamina y sus usos
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
EA201690371A1 (ru) Пиридазиноновые соединения и их применение
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
BR112015023349A2 (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
EA201590353A1 (ru) Способы лечения болезни альцгеймера и фармацевтические композиции
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
DOP2016000253A (es) Nuevos compuestos
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
BR112017019728A2 (pt) combinações e formulações de dose fixa compreendendo etc1002 e uma ou mais estatinas e método para tratar ou reduzir o risco de doença cardiovascular
BR112017003334A2 (pt) variantes de desintegrina e usos farmacêuticos destas
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
CL2016002267A1 (es) Ureas asimétricas p-sustituidas y usos médicos de las mismas
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
CL2017002229A1 (es) Inhibidores de bace1.
NI201700066A (es) Antagonistas de a2a de dosis baja para tratamiento de tdah y la enfermedad de parkinson
BR112016016098A2 (pt) Compostos orgânicos
BR112016014236A2 (pt) Agente profilático e terapêutico para o distúrbio do déficit de atenção/hiperatividade
EA201201123A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения обсессивно-компульсивного расстройства (окр)
BR112018007213A2 (pt) composto, formulação de fragrância, métodos para melhorar, intensificar ou modificar uma formulação de fragrância e para neutralizar odor desagradável, e, produto de fragrância.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2701 DE 11-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.